|
|
News Archive
- CryoCath Appoints Vice President, Europe
7/2/2008
- CryoCath Introduces Arctic Front in Italy, Belgium and Spain
6/27/2008
- CryoCath Closes Exercise of Over-Allotment Option
6/6/2008
- CryoCath Announces Exercise of Over-Allotment Option
6/5/2008
- CryoCath Introduces Arctic Front in Hong Kong
6/4/2008
- CryoCath Presents at Prestigious Heart Rhythm Society Meeting
5/20/2008
- CryoCath Announces Fiscal 2008 Second Quarter Results
5/12/2008
- CryoCath Completes $17.4 Million Bought Deal of Common Shares
5/7/2008
- CryoCath to Hold Second Quarter 2008 Conference Call and Webcast
4/30/2008
- CryoCath achieves key milestone of 270 consented patients for STOP AF IDE Trial
for its Arctic Front Atrial Fibrillation therapy system
4/29/2008
- CryoCath Enters into Agreement for a $17.4 Million Bought Deal of Common Shares
4/17/2008
- CryoCath Reports Data Presented at the 74th Annual Meeting of the German Cardiac
Society
4/3/2008
- CryoCath Introduces Arctic Front in Australia
3/26/2008
- CryoCath Appoints New Chief Financial Officer
2/26/2008
- CryoCath Technologies Notice of Annual Meeting
2/20/2008
- CryoCath Announces Fiscal 2008 First Quarter Results
2/14/2008
- CryoCath Provides Update on Patent Infringement Lawsuit
2/14/2008
- CryoCath to Hold First Quarter 2008 Conference Call and Webcast
2/7/2008
- CryoCath intends to contest patent infringement claim by CryoCor, Inc.
1/17/2008
- CryoCath Announces 2007 Fourth Quarter and Fiscal Year End Financial Results
12/17/2007
- CryoCath to present at the 2007 RBC Healthcare Conference
12/6/2007
- CryoCath to present at Piper Jaffray and BMO Healthcare Conferences
11/27/2007
- CryoCath to Present at Canaccord Adams Cardiovascular Conference
11/9/2007
- CryoCath to Present at CIBC Healthcare Conference
10/30/2007
- CryoCath Reports Positive 12-Month Follow up Data from U.S. AFIB Trial
10/25/2007
- CryoCath Files Patent Infringement Lawsuit
10/16/2007
- CryoCath Announces Addition to Board of Directors
8/30/2007
- CryoCath Announces Fiscal 2007 Third Quarter Results
8/9/2007
- CryoCath Completes Sale to ATS Medical
6/28/2007
- CryoCath Reports Positive Data at European Society of Cardiology Conference
6/28/2007
- CryoCath to Sell Surgical Portfolio to ATS Medical in US$22 Million Transaction
6/19/2007
- CryoCath to present at Leerink Swann - Rhythm Revival: Atrial Fibrillation
Roundtable Conference
6/5/2007
- CryoCath Announces Fiscal 2007 Second Quarter Results
5/15/2007
- CryoCath Featured Prominently at 2007 Annual Scientific Sessions of the Heart
Rhythm Society
5/8/2007
- CryoCath reports positive data at German Cardiac Society conference
4/18/2007
- CryoCath receives FDA approval to expand STOP AF trial to full cohort of patients
3/28/2007
- CryoCath Reports Positive 6-Month Follow up Data from U.S. AFIB Trial
3/8/2007
- CryoCath announces fiscal 2007 first quarter financial results
2/13/2007
- CryoCath Announces New President and CEO
1/29/2007
- CryoCath treats first patients with new SurgiFrost XL
1/4/2007
- CryoCath announces 2006 fourth quarter and fiscal year end financial results
12/21/2006
- CryoCath hires chief financial officer
12/15/2006
- CryoCath provides twelve month update on pivotal AF study
12/12/2006
- CryoCath to present at 2006 RBC Capital Markets Health Care Conference
12/7/2006
- CryoCath receives FDA approval to expand AF trial
11/28/2006
- CryoCath named to Deloitte’s Technology Fast 500
11/14/2006
- CryoCath enrolls first patient in U.S. AF trial
10/19/2006
- CRYOCATH TO PRESENT AT 2006 UBS GLOBAL LIFE SCIENCES CONFERENCE
9/26/2006
- CRYOCATH RECEIVES FDA APPROVAL TO START AF TRIAL
9/5/2006
- CRYOCATH ANNOUNCES FISCAL 2006 THIRD QUARTER RESULTS
8/14/2006
- CRYOCATH ANNOUNCES MANAGEMENT CHANGE
7/20/2006
- CRYOCATH REPORTS POSITIVE AF DATA AT MAJOR EUROPEAN CONFERENCE
6/19/2006
- CRYOCATH PROMINENT AT LEADING SCIENTIFIC CONFERENCE
5/23/2006
- CRYOCATH ANNOUNCES FISCAL 2006 SECOND QUARTER RESULTS
5/10/2006
- CRYOCATH REPORTS POSITIVE AF DATA AT EUROPEAN CARDIAC CONFERENCE
4/24/2006
- CRYOCATH PROVIDES UPDATE ON PIVOTAL AF STUDY
4/3/2006
- CryoCath Announces Fiscal 2006 First Quarter Results
2/14/2006
- CRYOCATH ANNOUNCES MANAGEMENT CHANGES
1/20/2006
- CRYOCATH REPORTS POSITIVE DATA AT ATRIAL FIBRILLATION CONFERENCE
1/16/2006
- CryoCath Announces 2005 Fourth Quarter and Fiscal Year End Financial Results
12/5/2005
- CRYOCATH ANNOUNCES THE EXTENSION OF THE TERM OF THE OPTION GRANTED TO
INVESTISSEMENT QUÉBEC
11/29/2005
- CryoCath to Present at CIBC World Markets 16th Annual Healthcare Conference
11/7/2005
- CryoCath Reports Positive 12-month Data for Arctic Front™
9/6/2005
- CryoCath Announces Fiscal 2005 Third Quarter Results
8/11/2005
- CryoCath Launches FrostByte™ Globally
7/20/2005
- CryoCath Receives European Approval for Arctic Front™ System
7/18/2005
- CryoCath’s U.S. Trial for Atrial Fibrillation Underway
6/15/2005
- CryoCath Announces Fiscal 2005 Second Quarter Results
5/12/2005
- CryoCath Receives FDA Approval to Initiate Arctic Front IDE for the Treatment of
Atrial Fibrillation
3/29/2005
- CryoCath Announces Fiscal 2005 First Quarter Results
2/14/2005
- CryoCath Reports Strong Chronic AF Results
1/17/2005
- CryoCath announces exercise of over-allotment option
1/13/2005
- CryoCath Closes $25,000,300 Bought Deal of Common Shares
12/14/2004
- CryoCath Receives Regulatory Approval to Market Freezor® and Arctic Circler® in China
11/29/2004
- CryoCath Enters into Agreement for a $25 Million Bought Deal of Common Shares
11/23/2004
- CryoCath Announces Record 2004 Fourth Quarter and Fiscal Year End Financial Results
11/11/2004
- CryoCath’s Freezor MAX Obtains FDA Approval in the U.S.
11/10/2004
- CryoCath & ATS Medical Enter Exclusive Global Partnership
11/9/2004
- CryoCath Provides AF Program Update
10/28/2004
- CryoCath Announces 2004 Third Quarter Financial Results
8/12/2004
- CryoCath Completes Enrollment in First Stage of Atrial Fibrillation Study
5/27/2004
- CryoCath Announces 2004 Second Quarter Financial Results
5/12/2004
- CryoCath Announces Exciting Start in Atrial Fibrillation Study With Arctic Circler™ Balloon
5/10/2004
- CryoCath's FrostByte Receives FDA Clearance, Company Poised to Launch
5/5/2004
- CryoCath Announces 2004 First Quarter Financial Results
2/26/2004
- CryoCath's SurgiFrost® Achieves over 90% Success Rates in Treating Atrial Fibrillation
1/27/2004
- CryoCath Announces 2003 Fourth Quarter and Year-end Financial Results
12/18/2003
- CryoCath Initiates Patient Enrolment in Atrial Fibrillation Study
11/17/2003
- CryoCath's Arctic Circler Highlighted at AHA™
11/13/2003
- CryoCath’s Freezor® MAX And Freezor® Xtra Successes in Treating Atrial Flutter Reported at International Conference
10/14/2003
- CryoCath Closes $25 Million Bought Deal of Common Shares
10/10/2003
- CryoCath Finalizes Biolevier Loan Agreement with Investissement Quebec
9/29/2003
- CryoCath Enters into Agreement for a $25 Million Bought Deal of Common Shares
9/22/2003
- CryoCath's Progress Reported at Analyst Forum
9/11/2003
- CryoCath Receives FDA Approval To Start Atrial Fibrillation Study
9/10/2003
- CryoCath Announces Third Quarter 2003 Financial Results
8/28/2003
- CryoCath Takes Voluntary Field Action to Replace Select Catheter Lots
8/19/2003
- CryoCath Receives European Approval for CryoVasc™
7/8/2003
- CryoCath Announces Second Quarter 2003 Financial Results
5/29/2003
- CryoCath's Freezor® MAX Successfully Treats First Atrial Flutter Cases
5/22/2003
- CryoCath Gains Key U.S. Patent to Promote Angiogenesis
5/13/2003
- CryoCath Receives European Approval for Freezor® MAX
5/12/2003
- CryoCath Receives FDA 510(k) Clearance for Freezor® Xtra
5/8/2003
- CryoCath Reports First Commercial Use of Freezor® System in U.S.
5/5/2003
- CryoCath Updates Arctic CirclerTM Progress
4/28/2003
- CryoCath Receives FDA Approval For Freezor®
4/22/2003
- CryoCath Fortifies Position in Strategic Surgical Ablation Market
4/15/2003
- CryoCath’s Freezor® Catheter Recommended For Approval By FDA Expert Panel
3/7/2003
- CryoCath Announces Record First Quarter 2003 Financial Results
2/26/2003
- CryoCath Appoints New Chairman
1/30/2003
- CryoCath Announces Fourth Quarter 2002 and Year End Financial Results
1/24/2003
- CryoCath Receives Positive FDA Inspection
1/22/2003
- CryoCath Appoints Robert Mattioli, Vice President North American Sales & Global EP Marketing
1/7/2003
- CryoCath’s Freezor™ PMA Application Advances
12/17/2002
- CryoCath Reports New Clinical Application for Freezor™
12/12/2002
- CryoCath Appoints Gerard Mahoudeau, Director, European Business
10/28/2002
- CryoCath Submits Final Module to FDA for U.S. Approval of the Freezor™ Cryoablation System
10/24/2002
- Interim Results of the “ICE” Cryotherapy Restenosis Trial Reported at TCT
9/30/2002
- CryoCath Appoints Japan Lifeline as Distributor in Japan
9/25/2002
- CryoCath Announces European Regulatory Approval for Arctic Circler™
9/17/2002
- CryoCath Closes Bought Deal Financing
9/10/2002
- CryoCath Files Final Prospectus For $18 Million Bought Deal of Units
8/30/2002
- CryoCath Announces Third Quarter Financial Results
8/29/2002
- CryoCath Files Preliminary Prospectus For $18 Million Bought Deal of Units
8/26/2002
- CryoCath Enters Into Agreement For A $18 Million Bought Deal of Units
8/21/2002
- CryoCath Announces First Commercial Use of SurgiFrost™ In the USA
7/11/2002
- CryoCath Receives FDA Acceptance for First Module of PMA Application for Freezor™
6/20/2002
- CryoCath Launches Surgifrost™ Surgical Cryoablation System in the United States
6/12/2002
- CryoCath Announces Second Quarter Financial Results
5/30/2002
- CryoCath Announces Successful Pediatric Use of Freezor™
4/24/2002
- CryoCath Completes Enrollment in “FROSTY” Pivotal IDE Study For Freezor™
4/17/2002
- CryoCath Announces Successful First Use of SurgiFrost™
4/11/2002
- CryoCath Reports Final Results of Ischemia Study
3/18/2002
- CryoCath Technologies File Final Prospectus Qualifying Distribution Of Shares Issuable Upon Exercise Of Special Warrants
2/27/2002
- CryoCath Achieves Strong Sales Growth in First Quarter
2/26/2002
- CryoCath Receives European Approval For Freezor™ Xtra
2/26/2002
- CryoCath Makes Two Strategic Appointments
2/7/2002
- CryoCath Joins TSE 300 Index
1/24/2002
- CryoCath Receives Approval to Sell Freezor™
Catheter System in Canada
1/22/2002
- CryoCath Gets FDA Approval for Modular Filing Plan for PMA Application for Freezor™ System
1/15/2002
- CryoCath Announces Year-End 2001 Financial Results
1/9/2002
- CryoCath Announces Webcast of 2001 Year-end Results
1/7/2002
- CryoCath enters into agreement for a $21 million bought deal of special warrants
12/10/2001
- CryoCath Announces First Human Clinical Use of Arctic Circler™ to Treat Atrial Fibrillation
12/6/2001
- Cryoablation’s Superior Safety Profiled at Major Cardiology Conference
11/14/2001
- CryoCath Announces Strong European Sales Growth in Fourth Quarter
10/18/2001
- Endocare and CryoCath form strategic alliance to penetrate surgical cardiac arrhythmia market
9/25/2001
- Erratum
8/31/2001
- CryoCath Announces Third Quarter 2001 Financial Results
8/28/2001
- CryoCath’s European launch gathering momentum
6/21/2001
- CryoCath gains key U.S. method patent to treat restenosis
6/6/2001
- CryoCath Announces Second Quarter 2001 Financial Results
5/29/2001
- Live Telecast of CryoCath’s Freezor™ Cardiac CryoAblation Procedure Receives Enthusiastic Reception at Prestigious International Conference
5/7/2001
- CryoCath’s Freezor™ Cardiac CryoAblation System Approved for Sale Across Europe.
3/29/2001
- CryoCath takes important step towards U.S. approval
with start of pivotal clinical trial
3/20/2001
- CryoCath Announces First Quarter 2001 Financial Results
2/27/2001
- CryoCath successfully initiates clinical feasibility study to treat restenosis with cryotherapy
2/22/2001
- CryoCath Announces Year-End 2000 Financial Results
2/16/2001
- CryoCath Announces the World’s First Catheter-based Cryoablation Procedure for the Treatment of Atrial Fibrillation (AF)
12/11/2000
- CryoCath Successfully Initiates Clinical Studies with its New 7F Freezor™ Catheter Cryotherapy System
11/30/2000
- CryoCath Technologies Announces Change in Fiscal Year
11/28/2000
- CryoCath Initiates Enrollment in its Pilot-study of Low-temperature Angiogenic Revascularization (POLAR) Study
11/16/2000
- CryoCath Technologies Raises $40 Million in Initial Public Offering of Shares Listed for Trading on TSE
10/31/2000
- CryoCath Technologies Announces Receipt of CE Mark
6/15/2000
- CryoCath Closes Largest Placement Ever For a Private Canadian Medical Devices Company
6/7/2000
- CryoCath Technologies Inc. Announces the Successful Start of Clinical Trials Using the Frostline™ Linear Cryoablation System
6/1/2000
- CryoCath Technologies Appoints Katherine Crewe, P.Eng. as Vice-President, Operations
5/18/2000
- CryoCath Technologies Receives ISO 9001 Certification
5/11/2000
- CryoCath Technologies Appoints David A. Smith as Vice President, Marketing and Sales
5/8/2000
- CryoCath Technologies Appoints Willard W. (Bill) Hennemann, PhD as Vice-President, Research and Development
1/24/2000
- CryoCath Technologies Treats First Three Patients of Multi-center Investigational Device Exemption in the USA
1/12/2000
- CryoCath Technologies Expands Study in Catheter Cryoablation of Cardiac Arrhythmia Following FDA Provisional Approval
11/18/1999
- CryoCath Technologies Strengthens its Dominant Intellectual Property Position in Catheter-based Cryoablation
9/7/1999
- CryoCath Technologies Announces New Cardiovascular Catheter Systems Development and Pilot Production Facility in Kirkland, Québec
5/21/1999
- CryoCath Successfully Expands its Human Clinical Studies for Cardiac Arrhythmia
5/13/1999
- CryoCath Completes a Third-Round Private Placement for CDN$10 Million
4/7/1999
- CryoCath Technologies’ Pioneering Efforts in Restenosis Receives Significant Support from the National Research Council of Canada
1/21/1999
- CryoCath Technologies Inc. Successfully Treats First Cardiac Arrhythmia Patient
9/21/1998
- CryoCath names Donald J. Larnard, Ph.D., Chief Technology Officer
2/9/1998
- CryoCath Technologies Raises $14.6 Million (CDN) in Second Round of Financing
1/30/1998
|
|
